• Molecular NameSulfadoxine
  • SynonymNA
  • Weight310.334
  • Drugbank_IDDB01299
  • ACS_NO2447-57-6
  • Show 2D model
  • LogP (experiment)1.06
  • LogP (predicted, AB/LogP v2.0)0.79
  • pkaN/A
  • LogD (pH=7, predicted)0.07
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.24
  • LogSw (predicted, AB/LogsW2.0)0.76
  • Sw (mg/ml) (predicted, ACD/Labs)0.42
  • No.of HBond Donors3
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds5
  • TPSA124.81
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn ultra-long-lasting sulfonamide often used in combination with pyrimethamine to treat or prevent malaria.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding90.0
  • Volume of distribution (VD)0.13 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmAbout 5% of sulfadoxine appears in the plasma as acetylated metabolite, about 2 to 3% as the glucuronide. Pyrimethamine is transformed to several unidentified metabolites.
  • Half life4~8 days
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAll major reactions to sulfonamides and to pyrimethamine could occur, even though they may not have been reported with Fansidar.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A